Caracterización de la nefropatía diabética en pacientes atendidos en el Hospital José María Velasco Ibarra noviembre 2018 – abril 2019

Abstract

A descriptive was conducted in a retrospective and cross-sectional study, the objective of the research work is to identify in the prevalence of Diabetic Nephropathy in patients diagnosed with Diabetes Mellitus at the José "Maria Velasco Ibarra de Tena Hospital”, between November 2018 and April 2019, with the analysing histories In patients with a diagnosis of DM, a sample is established that shows the following results: Renal pathology is generally associated with type 2 DM (90%), highlighting the female gender (55%), the predominant age group corresponds to the elderly patients of 60 years (57%). Guiding us in glycosylated haemoglobin, renal pathology presented emphatically with HbA1C values between 7.5 to 9% (56.86%) with a peak in the variable 125 and 180 mg / dl of basal glucose, which receive insulin treatment, depending on the creatinine albumin ratio, a greater propensity was observed with values between 29 and 299 mg / g and glomerular filtrates that pass between 60-89 ml/min and 30-44 ml/min. Emphasis is also placed on dyslipidaemias (70.59%) and AHT (52.94%) as comorbidities predisposing to renal pathology. Also, diabetic retinopathy (27%) stands out as the most frequent microvascular complication. The clinical variables of diagnostic support, as well as the time of evolution of the DM, fulfil a predictive role on which was supported to establish effective preventive as well as therapeutic management of the patients, taking into account determinants of the disease health process of the population under study, fundamental to improve the quality of life of the community. The integral management of the diabetic patient is recommended, with the periodic control of blood pressure, lipid profile, as well as checking the renal function in a patient with long-standing Diabetes Mellitus and also the adherence to the treatment for the underlying pathology; glycosylated haemoglobin every 3 months and glucose-based control.